NeoGenomics, Inc.
NEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.46 | 0.12 | -0.00 | 0.35 |
| FCF Yield | -8.15% | -7.56% | -42.21% | -11.10% |
| EV / EBITDA | -434.01 | -38.35 | -7.01 | -17.04 |
| Quality | ||||
| ROIC | -5.83% | -6.14% | -8.61% | -3.67% |
| Gross Margin | 43.92% | 41.34% | 36.86% | 38.62% |
| Cash Conversion Ratio | -0.09 | 0.02 | 0.46 | 3.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.02% | 6.90% | 4.67% | 5.81% |
| Free Cash Flow Growth | -10.85% | 68.31% | -6.62% | -228.79% |
| Safety | ||||
| Net Debt / EBITDA | -157.72 | -15.29 | -4.22 | -4.53 |
| Interest Coverage | -13.92 | -15.60 | -20.79 | -14.45 |
| Efficiency | ||||
| Inventory Turnover | 13.85 | 14.37 | 13.26 | 12.71 |
| Cash Conversion Cycle | 88.25 | 85.00 | 89.99 | 91.22 |